Hasty Briefsbeta

Bilingual

Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis - PubMed

3 hours ago
  • #multiple sclerosis
  • #B-cell depleting therapy
  • #psoriasis
  • A retrospective multicenter analysis examined psoriasis development or exacerbation in MS patients treated with B-cell depleting therapies.
  • Among 3,228 MS patients on B-cell therapies, 17 experienced psoriasis issues: 7 with new onset and 10 with worsening of existing psoriasis.
  • The median time to psoriasis onset or worsening was 13 months, with a range from 3 to 83 months during continuous therapy.
  • Most cases were managed with topical treatments, but severe instances required changes in MS therapy or initiation of psoriasis-specific immunotherapies.
  • The study concludes that psoriasis under B-cell depleting therapy is rare, manageable in most cases, but warrants further investigation into the immunological interplay.